Compare PRAX & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | DUOL |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.4B |
| IPO Year | 2020 | 2021 |
| Metric | PRAX | DUOL |
|---|---|---|
| Price | $289.43 | $100.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $572.13 | $176.88 |
| AVG Volume (30 Days) | 308.0K | ★ 2.9M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 355.85 |
| EPS | N/A | ★ 8.57 |
| Revenue | N/A | ★ $1,037,589,000.00 |
| Revenue This Year | N/A | $19.80 |
| Revenue Next Year | $6,395.88 | $14.64 |
| P/E Ratio | ★ N/A | $11.66 |
| Revenue Growth | N/A | ★ 38.71 |
| 52 Week Low | $26.70 | $91.99 |
| 52 Week High | $354.87 | $544.93 |
| Indicator | PRAX | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 40.28 |
| Support Level | $266.93 | $91.99 |
| Resistance Level | $322.32 | $118.42 |
| Average True Range (ATR) | 16.36 | 5.56 |
| MACD | -4.02 | 1.85 |
| Stochastic Oscillator | 4.20 | 49.08 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.